M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, et al: Predictive factors for acute and late urinary toxicity immediately after permanent prostate brachytherapy: long-term outcome in 712 consecutive individuals. Int J Radiat Oncol Biol Phys 2009, 73(four):1023?032. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A: The standardisation of terminology in reduce urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003, 61(1):37?9. Michel MC, Chapple CR: Comparison on the cardiovascular effects of tamsulosin oral controlled absorption method (OCAS) and alfuzosin prolonged release (XL). Eur Urol 2006, 49(3):501?08. discussion 508?09. Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, Arai Y: Nocturia and benign prostatic hyperplasia. Urology 2003, 61(four):786?90. Schwinn DA, Roehrborn CG: Alpha1-adrenoceptor subtypes and reduced urinary tract symptoms. Int J Urol 2008, 15(three):193?99. Brawer MK, Lin DW, Williford WO, Jones K, Lepor H: Effect of finasteride and/or terazosin on serum PSA: benefits of VA Cooperative Study #359. Prostate 1999, 39(4):234?39. Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshida M: Clinical guideline for male reduce urinary tract symptoms. Int J Urol 2009, 16(ten):775?90. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, et al: Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011, 185(5):1793?803. Committee for Establishment in the Clinical Guidelines for Nocturia with the Neurogenic Bladder Society:: Clinical recommendations for nocturia. Int J Urol 2010, 17(five):397?09. Bruskewitz RC, Larsen EH, Madsen PO, Dorflinger T: 3-year followup of urinary symptoms immediately after transurethral resection of the prostate. J Urol 1986, 136(three):613?15. Okada S, Watanabe H, Kojima Y, Yanai Y, Sasaki S, Kohri K: Loxoprofen sodium treatment for elderly males with refractory nocturia: impact on night-time urine production. Int J Urol 2008, 15(five):462?64.Kawahara et al. BMC Urology 2013, 13:30 http://biomedcentral/1471-2490/13/Page 6 of28. Abraham L, Hareendran A, Mills IW, Martin ML, Abrams P, Drake MJ, MacDonagh RP, Noble JG: Development and validation of a quality-of-life measure for guys with nocturia. Urology 2004, 63(three):481?86. 29. Klerman H, St Hilaire MA, Kronauer RE, Gooley JJ, Gronfier C, Hull JT, Lockley SW, Santhi N, Wang W, Klerman EB: Analysis system and experimental situations impact computed circadian phase from melatonin information.2791273-76-0 Order PLoS A single 2012, 7(four):e33836.916304-19-3 Chemscene 30.PMID:26446225 Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O: Symptom assessment tool for overactive bladder syndrome veractive bladder symptom score. Urology 2006, 68(2):318?23. 31. Gotoh M, Homma Y, Yokoyama O, Nishizawa O: Responsiveness and minimal clinically crucial alter in overactive bladder symptom score. Urology 2011, 78(4):768?73. 32. Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R: An epidemiological study of insomnia amongst the Japanese basic population. Sleep 2000, 23(1):41?7. 33. Liu X, Uchiyama M, Kim K, Okawa M, Shibui K, Kudo Y, Doi Y, Minowa M, Ogihara R: Sleep loss and daytime sleepiness in the basic adult population of Japan. Psychiatry Res 2000, 93(1):1?1. 34. Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Doctor 2007, 76(4):517?26. 35. Buscemi N, Vandermeer B, F.
